Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma

NCT04537442 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: IM21 CAR-T cells

Sponsor

Beijing Immunochina Medical Science & Technology Co., Ltd.